IL-7 promotes T cell proliferation through destabilization of p27\(^{Kip1}\)

Wen Qing Li,1 Qiong Jiang,1 Eiman Aleem,2 Philipp Kaldis,2 Annette R. Khaled,1 and Scott K. Durum1

1Laboratory of Molecular Immunoregulation and 2Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Frederick, MD 21702

Interleukin (IL)-7 is required for survival and homeostatic proliferation of T lymphocytes. The survival effect of IL-7 is primarily through regulation of Bcl-2 family members; however, the proliferative mechanism is unclear. It has not been determined whether the IL-7 receptor actually delivers a proliferative signal or whether, by promoting survival, proliferation results from signals other than the IL-7 receptor. We show that in an IL-7-dependent T cell line, cells protected from apoptosis nevertheless underwent cell cycle arrest after IL-7 withdrawal. This arrest was accompanied by up-regulation of the cyclin-dependent kinase inhibitor p27\(^{Kip1}\) through a posttranslational mechanism. Overexpression of p27\(^{Kip1}\) induced G1 arrest in the presence of IL-7, whereas knockdown of p27\(^{Kip1}\) promoted S phase entry after IL-7 withdrawal. CD4 or CD8 T cells transferred into IL-7-deficient hosts underwent G1 arrest, whereas 27\(^{Kip1}\)-deficient T cells underwent proliferation. We observed that IL-7 withdrawal activated protein kinase C (PKC)\(\beta\) and that inhibition of PKC\(\beta\) with a pharmacological inhibitor completely blocked the rise of p27\(^{Kip1}\) and rescued cells from G1 arrest. The conventional pathway to breakdown of p27\(^{Kip1}\) is mediated by S phase kinase-associated protein 2; however, our evidence suggests that PKC\(\beta\) acts via a distinct, unknown pathway inducing G1 arrest after IL-7 withdrawal from T cells. Hence, IL-7 maintains T cell proliferation through a novel pathway of p27\(^{Kip1}\) regulation.

The size of the peripheral T cell pool is tightly controlled through homeostatic mechanisms that regulate cell survival and proliferation. The cytokine IL-7, a product of nonlymphoid cells in lymphoid tissues, is one of the required stimuli for both survival and proliferation of most of the major subsets of peripheral T cells (1–7). Together with IL-7, weak signals from the TCR-recognizing self-peptide/MHC are required for survival and proliferation of naive CD4 and CD8 cells (1, 8, 9). Survival and proliferation of memory CD8 cells depends on IL-15 and IL-7 (2, 3). Memory CD4 cells become acutely dependent on IL-7 for homeostatic proliferation when TCR signaling is abolished (4).

Survival of T cells has been largely attributed to IL-7 regulation of the balance of proapoptotic versus antiapoptotic members of the Bcl-2 family. Thus, IL-7 protects T cells from death through the induction of antiapoptotic proteins Bcl-2 (10) and Mcl-1 (11), and inhibition of proapoptotic proteins Bax (12), Bad (13), and Bim (14). The proliferative mechanism of T cells in response to IL-7 has not been studied extensively. It has not been determined whether the IL-7 receptor delivers a proliferation signal per se, or alternatively whether the IL-7 effect is to maintain survival, permitting other signals to induce cell division.

As characterized in other cell types, proliferation depends on the activity of a series of protein complexes composed of cyclins and cyclin-dependent kinases (CDKs; reference 15). CDK activity is regulated through phosphorylation-dephosphorylation of the kinase subunit and in large part through inhibition by CDK inhibitors (CKIs; references 15 and 16). CKIs can be divided into two classes: inhibitors of CDK4 proteins (p16, p15, p18, and p19) and inhibitors of the Cip/Kip family (p21\(^{Cip1}\), p27\(^{Kip1}\), and p57\(^{Kip2}\)). p21\(^{Cip1}\) and p27\(^{Kip1}\) are able to constrain a broad spectrum of CDKs (16) and are expressed in peripheral T cells (17, 18). Mice lacking p27\(^{Kip1}\) display giantism with disproportionately enlarged lymphoid organs as a result of increased cellularity (19–21),
suggesting that p27Kip1 could be an inhibitor of homeostatic proliferation of T cells. Peripheral T cells from p27Kip1–
transgenic mice show a dramatically reduced ability to pro-
liferate in response to mitogenic stimulation (22). The role of
p21Cip1 in T lymphocytes is less clear, with some evidence sug-
gestig that it promotes T lymphocyte apoptosis mediated by
Fas or protects activated/memory T cells from apoptosis (23).

p27Kip1 plays a pivotal role in the control of cell cycle G1
to S phase transition by inhibiting the activities of G1 cyclins/
CDKs. In response to stimulation by growth factors, levels of
p27Kip1 dramatically decrease, which appears to be a critical
mechanism by which growth factors are capable of inducing
cell cycle progression. IL-3 repressed p27Kip1 transcription in
a murine pro–B cell line, Ba/F324, as did IL-2 in CTLL cells
(25). However, in most types of normal or transformed cells,
p27Kip1 is regulated posttranslationaly through ubiquitin-
ation and proteosomal degradation (26). Phosphorylation of
p27Kip1 at threonine 187 (T187) by CDK2–cyclin E com-
plexes is thought to initiate the major pathway for p27 Kip1
protein degradation (27, 28). Several studies indicate that
S phase kinase-associated protein 2 (Skp2), an F-box protein,
functions as the receptor component of an SCF ubiquitin
ligase complex, binding to p27Kip1 in conjunction with CDK
subunit 1 (Cks1) only when T187 of p27 Kip1 is phosphory-
lated. This results in the ubiquitination and degradation of
p27Kip1 (29–31).

IL-7 has been previously reported to down-regulate
p27Kip1 in T cell acute lymphoblastic leukemia cells, and this
was proposed to promote clonal expansion of these trans-
formed cells (32, 33). To understand how IL-7 affects cell
cycle in nontransformed T cells, we evaluated the role of
p27Kip1 in proliferation in an IL-7–dependent thymocyte line
(ablated). This results in the ubiquitination and degradation of
p27Kip1 (29–31).

IL-7 has been previously reported to down-regulate
p27Kip1 in T cell acute lymphoblastic leukemia cells, and this
was proposed to promote clonal expansion of these trans-
formed cells (32, 33). To understand how IL-7 affects cell
cycle in nontransformed T cells, we evaluated the role of
p27Kip1 in proliferation in an IL-7–dependent thymocyte line
and in peripheral T cells in vivo, and we observed two path-
ways, Skp2– and protein kinase C (PKC)θ-dependent, by
which IL-7 receptor regulates p27Kip1 degradation.

RESULTS

Bcl-2 cannot replace the requirement for IL-7
in promoting cell proliferation

IL-7 promotes survival by maintaining a favorable balance of
Bcl-2 family members in which antiapoptotic proteins protect
from proapoptotic proteins. One of the actions of IL-7 is to
induce the synthesis of the antiapoptotic protein Bcl-2 (10),
and transgenic expression of bcl-2 has been shown to par-
tially overcome the requirement for IL-7 for thymopoiesis
(34). Although thymopoiesis requires both cell survival and
proliferation, it was possible that IL-7 signaling did not in-
duce proliferation directly but blocked apoptosis, thereby per-
mitting other proliferative signals to drive the expansion of
T cells. Because the D1 thymocyte line (35) responds to IL-7
by survival and proliferation, we examined to what extent
overexpression of bcl-2 could replace the IL-7 signal by stably
transfecting D1 cells with a bcl-2 retroviral expression vector.
As shown in Fig. 1, withdrawal of IL-7 for 24 h from un-
transfected D1 cells induced both G1 arrest and ~50% of cells
died. However, bcl-2–transfected D1 cells could survive in-
definitely without IL-7 but nevertheless underwent G1 arrest.
Restimulation of bcl-2–transfected cells with IL-7 restored a
normal rate of proliferation (not depicted). Thus, Bcl-2 could
replace the survival function of IL-7 but failed to replace the
proliferative function, indicating that IL-7 induces a prolifera-
tion pathway that is distinct from the ant apoptotic pathway.

IL-7 down-regulates p27Kip1 via posttranslational regulation

Entry into S phase can be inhibited by the CKI p27Kip1, and
it has been shown that IL-3 and IL-2 block p27Kip1 gene ex-
pression (24, 25). It was reported that in IL-7–responsive
T cell acute lymphoblastic leukemia cells, both survival and
cell division correlated with low levels of p27Kip1 protein
(33). Therefore, we examined whether IL-7 influenced the
expression of p27Kip1 in D1 cells or LN T cells. Western blot-
ting analysis revealed that after IL-7 withdrawal from D1
cells, p27Kip1 protein levels rose dramatically, whereas levels
of another CKI, p16, remained unchanged (Fig. 2 A). p21Cip1,
another CKI, was undetectable in D1 cells (not depicted).
p27Kip1 protein levels also increased in primary cultures of
T cells after 24 h of IL-7 deprivation. Both p16 and p21Cip1
expressions were not affected by IL-7 withdrawal in LN cells
(Fig. 2 B). Overexpression of bcl-2 in D1 cells altered neither
cell cycle status (Fig. 1) nor p27Kip1 expression (Fig. 2 C).
To determine whether IL-7 regulated p27Kip1 at the transcrip-
tional level, we performed Northern blotting. Withdrawal of
IL-7 from D1 cells did not increase the mRNA levels of p27kip1 (Fig. 2 D). Therefore, unlike IL-3 or IL-2, IL-7 down-regulated p27Kip1 at a posttranslational level rather than at the transcriptional level.

**p27Kip1 induces G1 arrest in D1 cells**

To determine if p27Kip1 could contribute to G1 arrest after IL-7 withdrawal, D1 cells were transfected with p27Kip1 in a retroviral expression vector expressing GFP as a selective marker. 20 h later, GFP+ cells were sorted and placed in culture with IL-7. D1 cells or p27Kip1-transfected D1 cells were stained with propidium iodide (PI) and cell cycle status was analyzed by flow cytometry. As shown in Fig. 3, in the presence of IL-7, overexpression of p27Kip1 in D1 cells induced complete G1 arrest 36 h after transfection and no apoptosis was observed.

To determine whether p27Kip1 was required for G1 arrest after IL-7 withdrawal, we introduced a small interfering RNA (siRNA), pMIG-hU6-sip27Kip1 (sip27Kip1), to knockdown expression of endogenous p27kip1 in D1 cells. The expression of p27Kip1 was strongly inhibited by sip27Kip1 at 15 h after IL-7 deprivation, whereas the control-scrambled siRNA showed no effect (Fig. 4, top). PI staining analysis showed that cell cycle progression into S phase after IL-7 withdrawal was also enhanced by sip27Kip1. After 15 h of IL-7 deprivation, the number of cells bearing sip27Kip1 in S phase increased to 28.55%, as compared with 18.36% of that in control cells (Fig. 4, bottom). There was no difference in cell survival between D1 with sip27Kip1 and D1 with siRNA control (Fig. 4, bottom). These data implicate the up-regulation of p27Kip1 as an important mediator of G1 arrest after IL-7 withdrawal.

**p27Kip1 deficiency partially restores T cell proliferation in IL-7-deficient hosts**

Having shown that in the D1 thymic cell line p27Kip1 plays an important role in cell cycle arrest after IL-7 withdrawal, we tested this model using peripheral T cells in vivo. After transfer of T cells into a host depleted of lymphocytes, the survival and expansion of most subsets requires IL-7 (1, 3). This is termed the “homeostatic” role of IL-7, distinct from the thymopoietic role, enabling us to evaluate the role of p27Kip1 in IL-7 signaling in normal T cells. LN cells from p27Kip1 KO or C57BL/6 (WT) mice were labeled with CFSE and transferred into sublethally irradiated Rag−/− or IL-7−/−/Rag−/− recipient mice. 6 d after transfer, donor cell homeostatic proliferation profiles were analyzed by staining with anti-CD4 or anti-CD8 followed by flow cytometry. The recoveries of CFSE+ donor cells per mouse were as follows: 9.8 ± 2.8 × 10^4
(p27Kip1 KO into Rag−/− host), 9.0 ± 1.2 × 10^4 (WT into Rag−/− host), 4.1 ± 1 × 10^4 (p27Kip1 KO into IL-7−/−/Rag−/− host), and 3.1 ± 0.9 × 10^4 (WT into IL-7−/−/Rag−/− host). These recoveries of CFSE+ cells are in the range of 2–5% of cells transferred into IL-7–dependent hosts, comparable to similar published studies. As shown in Fig. 5, the proliferation of CD8 cells was faster (79.6% of WT and 80.4% of p27Kip1 KO cells underwent six divisions) compared with CD4 cells (52.2% of WT and 53.8% of p27Kip1 KO cells underwent three to four divisions; Fig. 5, A and B). In agreement with previous studies, homoeostatic survival and proliferation of peripheral T cells was dramatically reduced in IL-7−/−/Rag−/− mice (20.3% of CD4 and 38.9% of CD8 cells had divided), as compared with that in Rag−/− hosts (52.2% of CD4 and 79.6% of CD8 cells had divided; Fig. 5, B and D). Because cell death eventually occurs in the absence of IL-7, we chose an early time point (6 d) at which cell cycle arrest occurred in many cells before they died. About 20.3% of WT CD4 cells underwent just one division, and 38.9% of WT CD8 cells underwent two divisions in IL-7−/−/Rag−/− hosts (Fig. 5 D). p27Kip1 deficiency enhanced both CD4 and CD8 cell proliferation in the absence of IL-7. In comparison with WT cells in IL-7−/−/Rag−/− hosts, 42.9% of p27Kip1-deficient CD4 cells underwent two divisions, and 53.4% of p27Kip1-deficient CD8 cells underwent four divisions (Fig. 5, C and D). p27Kip1 deficiency did not completely replace the IL-7 signal (42.9 vs. 52.2% of proliferated CD4 and 53.4 vs. 79.6% of proliferated CD8; Fig. 5, B and C) because it would not be expected to protect from apoptosis. Hence, p27Kip1 is a key negative cell cycle regulator controlled by IL-7 in T cells.

**IL-7-induced p27Kip1 degradation mediated by Skp2-dependent and Skp2-independent/PKC-dependent pathways**

We then investigated the molecular mechanism of IL-7–induced p27Kip1 degradation. Phosphorylation of p27Kip1 at threonine 187 (T187) or serine 10 (S10) has been reported to affect its stability (36, 37). We examined whether p27Kip1 phosphorylation is regulated by IL-7 in D1 cells. D1 cells were deprived of IL-7 for various times, and as shown in Fig. 6 A, p27Kip1 protein levels began to rise within 4 h and continually increased up to 12 h after IL-7 withdrawal. The increase in p27Kip1 correlated with its phosphorylation at T187, whereas its phosphorylation at S10 remained unchanged (Fig. 6 A).

In the course of a previous study of cell death pathways, we had made the fortuitous observation that PKC inhibitors could affect cell cycle. Several studies have shown that PKCδ or PKCα could inhibit cell proliferation concomitant with increasing p27Kip1 protein levels in some cell types (38–40). Therefore, we assayed the impact of PKC inhibitors on p27Kip1 expression in D1 cells and observed that a PKC inhibitor, Gö6850 (inhibitor of classic and novel PKCs), blocked p27Kip1 up-regulation and decreased phosphorylation at T187 after IL-7 withdrawal, whereas the classic PKC inhibitor Gö6976 did not (Fig. 6 B). These data suggest that one of the novel PKCs is activated after IL-7 withdrawal and induces the accumulation of p27Kip1.

The phosphorylation of T187 rose in parallel to the rise in p27Kip1 protein, which was surprising because phospho–T187 was previously implicated in destabilizing the protein (28, 36). To examine whether T187 phosphorylation destabilized p27Kip1 protein in D1 cells, we generated p27Kip1 mutants. Replacing T187 with alanine (T187A) would prohibit phosphorylation, whereas replacing T187 with arginine (T187D) would mimic phosphorylation. FLAG-tagged p27Kip1 constructs (with GFP as a selective marker) were transfected into D1 cells, and 48 h later cell lyses were subjected to immunoblotting analysis with anti–FLAG and anti-GFP. The T187A mutant was higher than the WT protein level, suggesting that phosphorylation did in fact destabilize p27Kip1. Confirming this hypothesis, mimicking phosphorylation in the T187D mutant reduced p27Kip1 levels. As a control, p27Kip1 S10A-FLAG was detected at the same level as the WT, and equal GFP expression reflected the same transfection efficiency (Fig. 6 C). These data suggest that phosphorylation of T187 promotes p27Kip1 degradation, confirming previous studies. However, after IL-7 withdrawal, another mechanism (through a novel PKC) has a dominant stabilizing effect, resulting in a rise of both phosphorylated and nonphosphorylated p27Kip1.
T187 phosphorylation-dependent p27Kip1 degradation had been shown to require Skp2 and Cks1 (29, 30), and Skp2 and Cks1 expression is growth regulated and controlled by growth factors (41). Therefore, we examined the expression of Skp2 and Cks1 and observed that both Skp2 and Cks1 protein levels dropped after 12 h of IL-7 deprivation in D1 cells, suggesting that their decline could at least contribute to some of the accumulation of p27Kip1 at later time points. However, the PKC inhibitor Gö6850 did not prevent the decline of Skp2 and Cks1 (Fig. 6 D), although it blocked p27Kip1 accumulation (Fig. 6 B). Thus, the PKC pathway of p27Kip1 protein accumulation after IL-7 withdrawal in T cells is not through degradation of Skp2 and Cks1. Collectively, our findings indicate that two distinct mechanisms mediate...
IL-7–induced p27Kip1 degradation in T cells: (a) Skp2-/T187 phosphorylation-dependent pathway and (b) a pathway blocked by a novel PKC.

IL-7 deprivation activates PKCθ, and inhibition of PKCθ prevents G1 arrest

Having observed the involvement of a novel PKC in p27Kip1 up-regulation after IL-7 withdrawal, we then assessed which PKC isozyme is activated by IL-7 withdrawal. D1 cells were cultured with or without IL-7, and as shown in Fig. 7 A, PKCα, PKCβ, PKCδ, and PKCθ were present in D1 cells, but only PKCθ activation rose after IL-7 withdrawal. PKCθ activation occurred within 4 h after IL-7 withdrawal and remained activated up to 12 h (Fig. 7 B). To determine if PKC played a key role in cell cycle arrest, D1 cells were treated with the PKC inhibitor Gö6850 after withdrawal of IL-7. By blocking PKC activation, G1 to S phase transition was restored in D1 cells after withdrawal of IL-7 for 12 h (Fig. 7 C). The classical PKC inhibitor Gö6976 had no effect (not depicted). Our findings suggest that IL-7 withdrawal activated PKCθ, which, through an unknown mechanism, stabilizes p27Kip1 protein that in turn induces G1 arrest.

**DISCUSSION**

T lymphocytes depend on IL-7 for survival and homeostatic proliferation. The survival function of IL-7 is largely through maintaining a favorable balance of Bcl-2 family members. Here we show that IL-7 stimulates proliferation independently of survival and evaluate the role of the CKI p27Kip1.

We show that withdrawal of IL-7 induced G1 arrest and up-regulated p27Kip1. Overexpression of p27Kip1 induced G1 arrest in the presence of IL-7, and deletion of p27Kip1 partially replaced IL-7 in supporting T cell proliferation both in a cell line and in normal T cells in vivo. IL-7–induced p27Kip1 degradation involved two distinct mechanisms: the conventional Skp2-/T187 phosphorylation–dependent pathway and a Skp2-independent/PKCθ-dependent pathway that appeared to be the dominant mechanism. Fig. 8 illustrates one possible model that incorporates these hypotheses.

**Figure 7. PKCθ is activated and inhibition of PKCθ prevents cell cycle G1 arrest after IL-7 withdrawal.** (A) PKC activation was analyzed in D1 cells of IL-7 withdrawal for 12 h. Cell lysates were resolved by SDS-PAGE and immunoblotted using a phospho-PKC sample kit. Total PKCθ was measured as a loading control. (B) PKCθ activation was determined in D1 cells after IL-7 deprivation. Cell lysates were made from cells deprived of IL-7 for 4, 8, and 12 h, and PKCθ activation was assayed by immunoblotting using an antibody specific for PKCθ phosphorylation at threonine 538. (C) D1 cells were cultured without IL-7 and treated with 5 μM Gö6850 for 15 h. Cell cycle was analyzed by PI staining and the percentage of cells in different populations was calculated by ModFit LT software. Results were pooled from three experiments.
Embryonic fibroblasts from T187A p27Kip1 knockin mice retained some capacity to degrade p27Kip1 after serum starvation in embryonic fibroblasts (48). In CD4 T cells from these mice, although the ability of TCR signals to induce p27Kip1 breakdown was lost, high levels of IL-2 induced degradation of p27Kip1, suggesting the existence of a T187-independent pathway. Thus, IL-7 could induce a T187 phosphorylation-independent pathway, eliminating p27Kip1 in cycling T cells.

Phosphorylation of p27Kip1 at T187 has been shown to be required for Skp2-mediated p27Kip1 proteolysis (29), which also requires Cks1 association with Skp2 (30, 31). However, analysis of p27Kip1 ubiquitination in lymphocytes from Skp2−/− revealed a second pathway that was independent of Skp2 and T187 phosphorylation (49). Both pathways may be operating in the IL-7 response. IL-7 withdrawal eventually decreased both Skp2 and Cks1 expression (Fig. 6 D), and T187 phosphorylation somewhat destabilized p27Kip1 in D1 cells (Fig. 6 C). However, a PKC inhibitor prevented p27Kip1 protein accumulation despite the decline in Skp2 and Cks1 after IL-7 withdrawal (Fig. 6, B and D), suggesting an independent pathway. The latter appears the more dominant pathway because the PKC inhibitor was sufficient to relieve cell cycle arrest in the absence of IL-7 (Fig. 7).

Among the PKC isoforms, we observed that PKCθ was activated after IL-7 withdrawal and inhibition of PKCθ activity prevented cell cycle arrest (Fig. 7). PKCθ is predominantly expressed in T cells and promotes T cell proliferation induced by TCR and CD28 engagement (50). Our findings in the IL-7 pathway suggest that PKCθ can also block T cell proliferation by stabilizing p27Kip1 protein via a Skp2-independent mechanism. Because p27Kip1 lacks a consensus PKC phosphorylation target site, we hypothesize a novel intermediate that stabilizes p27Kip1 (Fig. 8).

In the IL-7 pathway, one candidate for conjugating ubiquitin to p27Kip1 is a newly identified ubiquitin-conjugating complex, Kip1 ubiquitination-promoting complex (KPC)1 and KPC2 (51, 52). This complex has been shown to induce breakdown of p27Kip1 during G1 phase in embryonic fibroblasts. The mechanism for regulating KPC during cell cycle is different from Skp2/Cks1, which is ubiquitinated and degraded in S-G2 phase. KPC is located in the cytosol where its levels remain constant throughout the cell cycle. During G1 phase, p27Kip1 is exported from the nucleus and targeted for degradation by KPC in the cytosol. IL-7 stimulation could therefore induce nuclear export of p27Kip1 and KPC-targeted degradation if it uses the mechanism of serum stimulation of embryonic fibroblasts. Alternatively, IL-7 stimulation could block nuclear import of human p27Kip1, which can be phosphorylated in its nuclear localization sequence by AKT (53–55); however, murine p27Kip1 lacks this site.

Our evidence suggests that Skp2/Cks1 is not the major pathway from IL-7 receptor to p27Kip1 degradation. This is relevant to a recent report that Skp2/Cks1 induces degradation not only of p27Kip1, but also of Rag2 (56), which is required for VDJ recombination in developing thymocytes. If IL-7 were to induce Skp2/Cks1, then Rag2 would degrade and interrupt
VDJ recombination, whereas the opposite is actually observed: IL-7 is required for VDJ recombination of the TCR-γ locus and facilitates rearrangement of other loci (27).

We recently reported that another proliferative pathway is regulated by IL-7 (58). The phosphatase Cdc25a removes an inhibitory phosphate from the active site of CDK2, and we observed that after IL-7 withdrawal, Cdc25a degrades downstream of a stress response. Thus, IL-7 stimulates CDK2 by two mechanisms: one by removing an inhibitory phosphate, and second, as reported here, by degrading an inhibitor, p27<sup>kip1</sup>. We have shown that both of these mechanisms are functionally important in normal T cells in that proliferation is induced, in the absence of IL-7, by introducing either a Cdc25a mutant that does not degrade or, as shown here, by eliminating p27<sup>kip1</sup>. These studies show that cell cycle regulation in lymphocytes can involve mechanisms that differ considerably from those in cell types previously studied, such as fibroblasts, and suggest that other proliferative stimuli in lymphocytes, in addition to IL-7, should be examined.

**MATERIALS AND METHODS**

**Mice.** p27<sup>kip1</sup>-deficient (p27<sup>/−</sup>−) mice (21), originally on a background mix of 129 and C57BL/6, were backcrossed onto C57BL/6 and maintained by heterozygous breeding. IL-7 (+) and −/− mice were obtained from R. Murray (EOS Biotechnology, San Francisco, CA). Rag<sup>/−</sup>− mice were purchased from The Jackson Laboratory. Both IL-7<sup>/−</sup>−/− and Rag<sup>/−</sup>− mice are maintained by homozygous breeding at the National Cancer Institute (NCI), Frederick Cancer Research and Development Center animal facility. NCI-Frederick Animal Care and Use Committee approved all experiments on mice.

**Cell lines.** The IL-7-dependent thymocyte cell line D1 was generated from p53 KO mice (35). D1 cells were maintained in RPMI 1640 supplemented with 10% fetal bovine serum (Hyclone), 2 mM l-glutamine, 1% penicillin-streptomycin, 50 μg/ml β-mercaptoethanol (Invitrogen), and 50 μg/ml murine recombinant IL-7 (PeproTech). Transfection used the retrovirus packaging cell line phoenix-Eco, maintained in DMEM supplemented with 10% FBS, 1% penicillin-streptomycin. The PKC inhibitors Gö6850 and Gö6976 were purchased from CalBiochem. PKC inhibitors Gö6850 and Gö6976 were purchased from CalBiochem.

**DNA constructs and retroviral infection.** The retroviral vector pMIG containing EGFP as marker and human hdl-2 retroviral expression vector was described previously (13). Mouse p27<sup>kip1</sup> cDNA construct pRc-p27<sup>kip1</sup> was provided by P. Coffey (University Medical Center, Utrecht, Netherlands; reference 24). The full-length p27<sup>kip1</sup> WT, mutant p27<sup>kip1</sup> T187A, T187D, and S10A cDNAs with FLAG epitope tags in the COOH terminus were amplified by PCR from pRc-p27<sup>kip1</sup> and cloned into the retroviral vector pMIG. Individual retroviral constructs were transfected into the phoenix-Eco package cell line using Fugene-6 reagent (13). The retrovirus-containing supernatants were harvested after 48 h and loaded onto a RetroNectin (TaKaRa)-coated plate, and then D1 cells were added and infected overnight. GFP<sup>−</sup> cells were sorted and analyzed.

**Antibodies and immunoblotting.** Rabbit anti-p27<sup>kip1</sup>, phospho-PKC antibody sampler kit, and goat anti-mouse IgG and goat anti-rabbit IgG coupled to horseradish peroxidase were purchased from Cell Signaling Biotechnology. Rabbit anti-phospho-T187–p27<sup>kip1</sup> was from CalBiochem. Mouse anti-PI38 (E-7) and rabbit anti-p16 were obtained from Santa Cruz Biotechnology, Inc. Rabbit anti-phospho-S10–p27<sup>kip1</sup>, mouse anti-Skp2, and rabbit anti-Cks1 were from Zymed Laboratories. Mouse anti–FLAG and mouse anti–GFP were from Stratagene. Mouse anti–p21 was purchased from BD Biosciences. 5 × 10<sup>5</sup> cells were lysed in Triton X-100 lysis buffer supplemented with protease inhibitor cocktails (Roche). 50 μg of protein lysates were resolved by SDS-PAGE on 12% Tris–Glycine gels (Invitrogen) and transferred to nitrocellulose membranes. Blots were probed with specific primary antibodies, followed by the appropriate secondary antibodies conjugated to horseradish peroxidase and then visualized by chemiluminescence. The chemiluminescent Western detection kit was purchased from Roche.

**Retrovirus-mediated siRNA.** The DNA nucleotides encoding mouse p27<sup>kip1</sup> siRNA (GenBank accession no. U09968, nucleotide 175–195) were ligated into pSilencer 2.1-U6 hygro (Ambion) under the expression of the human U6 promoter according to the manufacturer’s protocol. The DNA fragment containing human U6/p27<sup>kip1</sup> siRNA was amplified by PCR and ligated into the Sal I site of the retroviral vector pMIG to generate pMIG-hU6-sip27<sup>kip1</sup>. D1 cells were infected twice with pMIG-hU6-sip27<sup>kip1</sup> retrovirus and GFP<sup>−</sup> cells were sorted after 24 h of infection. Western blotting and PI staining were performed to analyze p27<sup>kip1</sup> protein expression and cell cycle.

**Cell cycle analysis.** Cell cycle was determined by PI staining as described previously (35). In brief, cells were placed in detergent buffer containing 50 μg/ml RNase A (Roche) at a concentration of 1–2 × 10<sup>5</sup> cells/ml and then mixed with an equal volume of PI (50 μg/ml; Sigma-Alrich) and incubated at room temperature in the dark for 1 h. DNA contents were assayed by flow cytometry. Data were analyzed using ModFit LT software.

**CFSE labeling and adoptive transfer of T cells.** LNs from p27<sup>kip1</sup> KO or WT mice were homogenized in RPMI 1640 containing 5% FBS and filtered through a 100-μm mesh nylon screen (BD Falcon). Red blood cells were removed with treatment by ACK lysis buffer (BioSource). LN cells were resuspended in PBS containing 5% FBS and warmed to 37°C. and then incubated for 10 min with 5 μM CFSE (Invitrogen) followed by two washes with PBS. 2–5 × 10<sup>5</sup> CFSE-labeled cells were suspended in PBS and adoptively transferred into IL-7<sup>/−</sup>−/− mice, together with 10<sup>5</sup> Rag<sup>/−</sup>− recipient mice by intravenous injection. The recipient mice received whole body γ-irradiation (600 cGy) at least 3 h before the injection. 6 d later, the host mice were killed and LN and spleen cells were stained with PE-Cy5–conjugated anti-CD4 (BD Biosciences) or PE-Cy5–conjugated anti-CD8 (BD Biosciences). The intensity of CFSE on donor cells was analyzed by gating on either CD4<sup>+</sup> or CD8<sup>+</sup> on a FACSscan flow cytometer.

We would like to thank Kathleen Noer, Roberta Mattthai, and Louise Finch for assistance with performing flow cytometry, and Rodney Wiles for technical work on animals. We are also grateful to Dr. Joost J. Oppenheim for comments on the manuscript.

This research was supported by the Intramural Research Program of the NIH, NCI. The authors have no conflicting financial interests.

Submitted: 28 July 2005
Accepted: 26 January 2006

**REFERENCES**

1. Tan, J.T., E. Dudli, E. LeRoy, R. Murray, J. Sprent, K.I. Weinberg, and C.D. Surh. 2001. IL-7 is critical for homeostatic proliferation and survival of naive T cells. Proc. Natl. Acad. Sci. USA. 98:8732–8737.

2. Tan, J.T., B. Ernst, W.C. Kieper, E. LeRoy, J. Sprent, and C.D. Surh. 2002. Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8<sup>+</sup> cells but are not required for memory phenotype CD4<sup>+</sup> cells. J. Exp. Med. 195:1523–1532.

3. Schluns, K.S., W.C. Kieper, S.C. Jameson, and L. Lefrancois. 2000. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat. Immunol. 1:426–432.

4. Seddon, B., P. Tomlinson, and B. Zamoyka. 2003. Interleukin 7 and T cell receptor signals regulate homeostasis of CD4 memory cells. Nat. Immunol. 4:680–686.

5. Kondrack, R.M., J. Harbertson, J.T. Tan, M.E. McBreen, C.D. Surh, and L.M. Bradley. 2003. Interleukin 7 regulates the survival and generation of memory CD4 cells. J. Exp. Med. 198:1797–1806.
24. Dijkers, P.F., R.H. Medema, C. Pals, L. Banerji, N.S. Thomas, E.W. Lam, C.D. Suth, W.L. Havran, and A.N. Theofilopoulos. 2005. Gamma delta T cell homeostasis is controlled by IL-7 and IL-15 together with subset-specific factors. J. Immunol. 174:4606–4612.

25. Stahl, M., P.F. Dijkers, G.J. Kops, S.M. Lens, P.J. Cofer, B.M. Burgerting, and R.H. Medema. 2002. The forkhead transcription factor FoxO regulates transcription of p27Kip1 and Bim in response to IL-2. J. Immunol. 168:5024–5031.

26. Pagano, M., S.W. Tam, A.M. Theodoras, P. Beer-Romero, G. Del Sal, V. Chua, P.R. Yew, G.F. Draetta, and M. Rolle. 1995. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science. 269:682–685.

27. Vlach, J., S. Hennecke, and B. Amati. 1997. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J. 16:5334–5344.

28. Sheaff, R.J., M. Groudine, M. Gordon, J.M. Roberts, and B.E. Chlum. 1997. Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev. 11:1464–1478.

29. Carrano, A.C., E. Eytan, A. Hershko, and M. Pagano. 1999. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat. Cell Biol. 1:193–199.

30. Ganoth, D., G. Bornstein, T.K. Ko, B. Larsen, M. Tyers, M. Pagano, and A. Hershko. 2001. The cell-cycle regulatory protein Cks1 is required for SCF(Skp2)-mediated ubiquitinylination of p27. Nat. Cell Biol. 3:321–324.

31. Spruck, C., H. Strohmayer, M. Watson, A.P. Smith, A. Ryan, T.W. Krek, and S.I. Reed. 2001. A CDK-independent function of mammalian Cks1: targeting of SCF(Skp2) to the CDK inhibitor p27Kip1. Mol. Cell. 7:639–650.

32. Barata, J.T., A. Silva, J.G. Brandao, L.M. Nadler, A.A. Cardoso, and V.A. Boussiotis. 2004. Activation of PI3K is indispensable for interleukin-7–mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells. J. Exp. Med. 200:659–669.

33. Barata, J.T., A.A. Cardoso, L.M. Nadler, and V.A. Boussiotis. 2001. Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase inhibitor p27. J. Immunol. 166:5735–5741.

34. Akashi, K., M. Kondo, U. Freeden-Jeff ry, R. Murray, and I.L. Weissman. 1997. Bcl-2 rescues T lymphopoiesis in interleukin-7 receptor-deficient mice. Cell. 89:1033–1041.

35. Kim, K., A.R. Khaled, D. Reynolds, H.A. Young, C.K. Lee, and S.K. Durum. 2001. Characterization of an interleukin-7–dependent thymic cell line derived from a p53(−/−) mouse. J. Immunol. Methods. 274:177–184.

36. Montagnoli, A., F. Fiore, E. Eytan, A.C. Carrano, G.F. Draetta, A. Hershko, and M. Pagano. 1999. Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trinemic complex formation. Genes Dev. 13:1181–1189.

37. Ishida, N., M. Kitagawa, S. Hatakeyama, and K. Nakayama. 2000. Phosphorylation at serine 10, a major phosphorylation site of p27Kip1, increases its protein stability. J. Biol. Chem. 275:25146–25154.

38. Vucenik, I., G. Ramakrishna, K. Tantivejkul, L.M. Anderson, and D. Durum. 2003. Characterization of an interleukin-7–dependent thymic cell survival and homeostatic proliferation in the periphery. Immunity. 11:173–181.

39. Nakayama, K., N. Ishida, M. Shirane, S. Hatakeyama, and K. Nakayama. 2000. Phosphorylation-dependent kinase inhibitor function of p27Kip1. J. Biol. Chem. 275:733–744.

40. Vlach, J., N. Ishida, M. Shirane, A. Inomata, T. Inoue, N. Nakayama, and K. Nakayama. 2000. Phosphorylation at serine 10, a major phosphorylation site of p27Kip1, increases its protein stability. J. Biol. Chem. 275:25146–25154.
45. O’Reilly, L.A., A.W. Harris, and A. Strasser. 1997. bcl-2 transgene expression promotes survival and reduces proliferation of CD3−CD4−CD8− T cell progenitors. *Int. Immunol.* 9:1291–1301.
46. Maraskovsky, E., L.A. O’Reilly, M. Teepe, L.M. Corcoran, J.J. Peschon, and A. Strasser. 1997. Bcl-2 can rescue T lymphocyte development in interleukin-7 receptor-deficient mice but not in mutant rag-1−/− mice. *Cell.* 89:1011–1019.
47. Hengst, L., and S.I. Reed. 1996. Translational control of p27Kip1 accumulation during the cell cycle. *Science.* 271:1861–1864.
48. Malek, N.P., H. Sundberg, S. McGrew, K. Nakayama, T.R. Kyriakides, and J.M. Roberts. 2001. A mouse knock-in model exposes sequential proteolytic pathways that regulate p27Kip1 in G1 and S phase. *Nat Rev.* 413:323–327.
49. Hara, T., T. Kamura, K. Nakayama, K. Oshikawa, S. Hatakeyama, and K. Nakayama. 2001. Degradation of p27(Kip1) at the G(0)-G(1) transition mediated by a Skp2-independent ubiquitination pathway. *J. Biol. Chem.* 276:48937–48943.
50. Isakov, N., and A. Altman. 2002. Protein kinase C(theta) in T cell activation. *Annu. Rev. Immunol.* 20:761–794.
51. Kamura, T., T. Hara, M. Matsumoto, N. Ishida, F. Okumura, S. Hatakeyama, M. Yoshida, K. Nakayama, and K.I. Nakayama. 2004. Cytoplasmic ubiquitin ligase KPC regulates proteolysis of p27(Kip1) at G1 phase. *Nat. Cell Biol.* 6:1229–1235.
52. Kotoshiba, S., T. Kamura, T. Hara, N. Ishida, and K.I. Nakayama. 2005. Molecular dissection of the interaction between p27 and Kip1 ubiquitylation-promoting complex, the ubiquitin ligase that regulates proteolysis of p27 in G1 phase. *J. Biol. Chem.* 280:17694–17700.
53. Liang, J., J. Zubovitz, T. Petrocsci, R. Kotchetkov, M.K. Connor, K. Han, J.H. Lee, S. Ciarallo, C. Catzavelos, R. Beniston, et al. 2002. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. *Nat. Med.* 8:1153–1160.
54. Viglietto, G., M.L. Motti, P. Brun, R.M. Melillo, A. D’Alessio, D. Caliﬁano, F. Vinci, G. Chiappetta, P. Tsichlis, A. Bellacosa, et al. 2002. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. *Nat. Med.* 8:1136–1144.
55. Shin, I., F.M. Yakos, F. Rojo, N.Y. Shin, A.V. Bakin, J. Baselga, and C.L. Arteaga. 2002. PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. *Nat. Med.* 8:1145–1152.
56. Jiang, H., F.C. Chang, A.E. Ross, J. Lee, K. Nakayama, K. Nakayama, and S. Desiderio. 2005. Ubiquitylation of RAG-2 by Skp2-SCF links destruction of the V(D)J recombinase to the cell cycle. *Mol. Cell.* 18:699–709.
57. Durum, S.K., S. Candeias, H. Nakajima, W.J. Leonard, A.M. Baird, L.J. Berg, and K. Muegge. 1998. Interleukin 7 receptor control of T cell receptor γ gene rearrangement: role of receptor-associated chains and locus accessibility. *J. Exp. Med.* 188:2233–2241.
58. Khaled, A.R., D.V. Bulavin, C. Kittipatarin, W.Q. Li, M. Alvarez, K. Kim, H.A. Young, A.J. Fornace, and S.K. Durum. 2005. Cytokine-driven cell cycling is mediated through Cdc25A. *J. Cell Biol.* 169:755–763.